sh5

SH5-07 is a hydroxamic acid-based Stat3 inhibitor (IC50: 3.9 μM).

SH-5, an AKT inhibitor potentiates apoptosis and inhibits invasion through the suppression of anti-apoptotic, proliferative and metastatic gene products regulated by IκBα kinase activation.

SH514 is a specific IRF4 inhibitor with an IC₅₀ of 2.63 µM, binding to the DNA-binding domain (IRF4-DBD) of IRF4 to block its transcriptional activity and inhibit the expression of downstream genes such as CCNC, CANX, E2F5, CMYC, HK2, and Blimp1, and inhibits the expression of MM cell cycle-related proteins CDC2, Cyclin B1, Cyclin D1, Cyclin E1, and CMYC, making it useful for studying multiple myeloma and malignant haematological diseases.

SH543 is a potent anti-osteoporosis agent that inhibits RANKL-induced osteoclastogenesis, with an IC50 value of 3.3 nM. It directly binds to KEAP1, activating the Nrf2-HO-1 antioxidant pathway, reducing reactive oxygen species (ROS) levels, and inhibiting PI3K-AKT and MAPK signaling pathways. SH543 alleviates pathological bone loss in ovariectomized mice and is useful for osteoporosis research.

Gedocarnil(ZK 113315) may be used to study diseases of the central nervous system.

ZSH-512 is a potent inhibitor of RARγ with antiproliferative properties. It induces apoptosis and reduces the expression of CD133, NANOG, SOX2, and EPCAM proteins. ZSH-512 exhibits anticancer activity and shows potential for colorectal cancer research.

Msh (5-10), cyclic, as a synthetic peptide, can conjugate with fatty acids for enhanced potency.